British Journal of Renal Medicine - 2019

Valuing health: solving the equation in renal disease
John Bradley
pp 3-3

Value in healthcare has been defined as health outcomes divided by cost. The first step in solving this equation and delivering value in healthcare is knowing how to measure both health outcomes and the cost of achieving them. Both are challenging.

BK nephropathy in the native kidneys of two non-transplant patients with haematological malignancies
Richard S Bodington and Sophia-Nicol Anastassiadou
pp 4-7

The BK virus (BKV) is a human polyomavirus. It was first isolated in 1971 and the first case of BK nephropathy (BKN) was reported in 1978.  It is the most important virus to infect the renal allograft, with BKN a well established and frequently encountered cause of graft dysfunction and loss. BKN in native kidneys is a far less common entity, although it has been increasingly described in recent years, with a number of cases reported among non-renal solid organ transplant, especially heart transplant, recipients and in those receiving bone marrow transplants for haematological malignancies. In addition, a very small number of cases of BKN in nontransplant patients have been described.

The NHS Long Term Plan
Donal J O’Donoghue
pp 8-9

The NHS Long Term Plan (previously known as the ten-year plan) was published in January 2019. It sets out key ambitions for the service over the next ten years.

Transforming Participation in Chronic Kidney Disease – is it possible to embed patient reported outcome measures to make a difference to care and the perception of care?
Rachel M Gair, Catherine Stannard, Sabine N Van der Veer and Richard Fluck
pp 10-13

Assessment of the success of treatments for renal patients has historically been based on measures considered important by the professionals delivering care; however, these measures do not capture many other outcomes, which are of real importance to patients and have a big impact on their care. These include the symptom burden, patients’ experience of care and their readiness to engage in their own care. Many of the instruments assessing the patient’s perspective have been available for decades, but their incorporation into routine clinical practice and pathways of care has been slow.

UK Kidney Week 2019
Paul Cockwell and Maarten Taal
pp 14-14

The Renal Association and British Renal Society will again host UK Kidney Week (UKKW) together, from 3rd to 5th June 2019 at the Hilton Metropole in Brighton. Many of you have contributed to shaping UKKW 2019 and theplanning for the meeting is almost complete.

Help and support for all kidney patients
Pauline Pinkos
pp 17-17

The National Kidney Federation (NKF) continues to offer help and support to all kidney patients throughout the UK. Our dedicated helpline is manned by fully trained advisers who are there to speak to patients about their renal concerns, which can be backed up by patient information leaflets that have been written especially for the NKF by medical professionals.

Iron trial results pave the way for improved haemodialysis treatment
Kidney Research UK
pp 17-17

An update of the results of the Kidney Research UK-facilitated Proactive IV irOn Therapy in haemodiALysis patients (PIVOTAL)trial, designed to determine the optimum dose of intravenous (IV) iron for a kidney patient on haemodialysis, has been published in the New England Journal of Medicine.

Balloon-assisted maturation: a valid option for arteriovenous fistulas that fail to mature?
Catarina Pereira Eusébio, Pedro Sousa, Mónica Fructuoso, Joana Ferreira, Catarina Prata and Teresa Morgado
pp 18-20

An arteriovenous fistula is the access of choice for haemodialysis (HD). Unfortunately, its success is limited by a high rate (28–53%) of maturation failure,  which represents the most significant shortcoming of this type of vascular access. Complications associated with vascular access account for elevated morbidity and mortality levels among HD patients, as well as increasing the financial cost of managing these patients. 

Vaccines for kidney transplant recipients: efficacy considerations and recommendations
Pallavi Patri, Brian Mark Churchill and Ruma Pal Ghosh
pp 21-27

Infection remains a major cause of morbidity and mortality among kidney transplant recipients; hence, protection against vaccine-preventable diseases is desirable. Guidelines recommend that every effort should be taken to complete the vaccination schedule prior to transplantation, as the immune response is better during this period compared with the immunosuppressed post-transplant period.

It's time to listen to patients. The third patient-reported experience measures (PREM) survey
Fiona Loud
pp 27-27

The results of the third patient-reported experience measures survey have just been released. This joint piece of work with the Renal Association tells us what nearly 14,000 kidney patients across the whole UK thought of their care in 2018. The questions were originally produced with patients and the survey is now validated by the University of Hertfordshire. The survey is also available in Welsh, Urdu and Gujurati. This year, for the first time and because patients had asked, there were free text boxes for people to add their comments. In addition to adding feedback on the questions, the comments attested to the value patients put on PatientView. Comments also emphasised the importance of continuity of care and reflected a negative experience where this was not possible. There was much praise for caring and supportive teams.

The British Journal of Renal Medicine was previously supported by Baxter Healthcare from 2011 to 2013, by Sandoz in 2011, by Shire Pharmaceuticals from 2006 to 2011, by Ortho Biotech and Shire Pharmaceuticals in 2005, by Ortho Biotech from 2000 to 2005 and by Janssen Cilag from 1996 to 2000.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly, the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title British Journal of Renal Medicine is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2021 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 1365-5604 (Print)  ISSN 2045-7839 (Online)